Advertisement

Fibrauretine reduces ischemia/reperfusion injury via RISK/eNOS activation

  • Chunsheng Wang
  • Rong Chang
  • Gan Gao
  • Xing Liu
  • Yingwei ZhangEmail author
Original Article
  • 26 Downloads

Abstract

Current studies have shown that fibrauretine can be used in the treatment of cardiovascular diseases; however, the protective mechanism of fibrauretine in cardiovascular diseases is unclear. The aim of this study was to investigate the effect and mechanism of fibrauretine in acute myocardial ischemia-reperfusion injury. We investigated the effects of glucocorticoid receptor/oestrogen receptor (GR/ER)-mediated Akt phosphorylation, extracellular regulated protein kinase (ERK1/2) activation and nitric oxide (NO) on the treatment of acute myocardial ischemia-reperfusion injury by fibrauretine. Myocardial ischemia-reperfusion (I/R) injury models were established in rats and gene-knockout mice, and the infarct size was measured. We detected the expression and phosphorylation of phosphatidylinositol-3 kinase (PI3K), protein kinase B (Akt), glucocorticoid receptor, oestrogen receptor, lactate dehydrogenase (LDH), creatine phosphokinase (CK-MB), stress-activated protein kinase (JNK), P38 protein kinase (P38 MAPK) and nitric oxide synthase (NOS) with or without the inhibitors to investigate the protective effect of fibrauretine on the heart. The results showed that fibrauretine can significantly reduce the myocardial infarction area in myocardial I/R injury, inhibit the activities of LDH and CK-MB in the serum, and increase the content of NO. However, the effects of fibrauretine on the reduction of the myocardial infarction area were eliminated by the PI3K inhibitor LY294002, Akt inhibitor IV, GR inhibitor RU468, ER inhibitor tamoxifen, eNOS inhibitor L-NAME and ERK1/2 inhibitor U0126. Moreover, in the case of WT mice and gene-knockout eNOS and iNOS mice, fibrauretine was able to significantly reduce the myocardial infarction area in iNOS−/− and wild type mice. However, there was no significant protective effect of fibrauretine in eNOS−/− mice. It is suggested that eNOS plays an important role in the protective effect of fibrauretine on the heart. Therefore, the results of this study show that the protective effect of fibrauretine on myocardial I/R injury is closely associated with eNOS expression, GR/ER-induced Akt phosphorylation and ERK1/2 activation.

Keywords

Fibrauretine Endothelial nitric oxide synthase RISK pathway Ischemia-reperfusion 

Notes

Author contribution

All the authors had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. YWZ and GG were responsible for the study concept and design. CSW and RC contributed to the acquisition of data. YWZ and XL assisted with data analysis and the interpretation of findings. CSW drafted the manuscript. YWZ and GG provided critical revisions of the manuscript for important intellectual content, obtained funding and supervised the study. All the authors approved the final version for publication.

Funding information

This work was supported by the Shenzhen Science and Technology Project (JCYJ20180306172459580).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical statement

The submitted manuscript involved animal research. All procedures adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The experiment was performed in compliance with the National Institutes of Health and institutional guidelines for the humane care of animals.

References

  1. Koushik R (2015) Recent advances in the diagnosis and treatment of acute myocardial infarction. World J Cardiol 7(5):243CrossRefGoogle Scholar
  2. Lindsey ML, Roberto B, Canty JM et al (2018) Guidelines for experimental models of myocardial ischemia and infarction. Am J Phys Heart Circ Phys 314(4):H812–H838Google Scholar
  3. Kalogeris T (2016) Ischemia/reperfusion. Compr Physiol 7(1):113CrossRefPubMedPubMedCentralGoogle Scholar
  4. Baines CP (2009) The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol 104(2):181–188CrossRefPubMedPubMedCentralGoogle Scholar
  5. Talukder MAH, Zweier JL, Periasamy M (2009) Targeting calcium transport in ischaemic heart disease. Cardiovasc Res 84(3):345–352CrossRefPubMedPubMedCentralGoogle Scholar
  6. Granger DN, Kvietys PR (2015) Reperfusion injury and reactive oxygen species: the evolution of a concept. Redox Biol 6:524–551CrossRefPubMedPubMedCentralGoogle Scholar
  7. Zweier JL, Flaherty JT, Weisfeldt ML (1987) Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci 84(5):1404–1407CrossRefGoogle Scholar
  8. Holly T A , Drincic A , Byun Y, Nakamura S., Harris K., Klocke F.J., Cryns V.L. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol, 1999, 31(9):0–1715, 1709CrossRefPubMedGoogle Scholar
  9. Daemen MARC, van t’ Veer C, Denecker G et al (1999) Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Investig 104(5):541–549CrossRefGoogle Scholar
  10. Toit EFD, Genis A, Opie LH et al (2008) A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 154(1):41–50CrossRefPubMedPubMedCentralGoogle Scholar
  11. Hausenloy DJ, Tsang A, Yellon DM (2005) The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15(2):69–75CrossRefGoogle Scholar
  12. Wang Z, Chen Z, Yang S, Wang Y, Huang Z, Gao J, Tu S, Rao Z (2014) Berberine ameliorates collagen-induced arthritis in rats associated with anti-inflammatory and anti-angiogenic effects. Inflammation 37(5):1789–1798CrossRefPubMedGoogle Scholar
  13. Tang Q-L, Min-Ling et al (2013) Antinociceptive effect of berberine on visceral hypersensitivity in rats. World J Gastroenterol 19(28):4582–4589CrossRefPubMedCentralGoogle Scholar
  14. Zhang Y, Wang X, Sha S, Liang S, Zhao L, Liu L, Chai N, Wang H, Wu K (2012) Berberine increases the expression of NHE3 and AQP4 in sennosideA-induced diarrhoea model. Fitoterapia 83(6):1014–1022CrossRefPubMedGoogle Scholar
  15. Zhifang X, Wei F, Qian S et al (2017) Rhizoma Coptidis and berberine as a natural drug to combat aging and aging-related diseases via anti-oxidation and AMPK activation. Aging Dis 8(6):760CrossRefGoogle Scholar
  16. Azimi G, Hakakian A, Ghanadian M, Joumaa A, Alamian S (2018) Bioassay-directed isolation of quaternary benzylisoquinolines from Berberis integerrima with bactericidal activity against Brucella abortus. Res Pharm Sci 13(2):149–158CrossRefPubMedPubMedCentralGoogle Scholar
  17. Huma A, Savita D (2013) Extraction optimization of, Tinospora cordifolia, and assessment of the anticancer activity of its alkaloid palmatine. Sci World J 2013:1–10CrossRefGoogle Scholar
  18. Durairajan SSK, Liu LF, Lu JH et al (2012) Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. Neurobiol Aging 33(12):2903–2919CrossRefPubMedGoogle Scholar
  19. Liu YQ, Cheng MC, Wang LX, Xiao HB (2010) Rhizoma coptidis and berberine-induced activation of murine microglia N9 cells. J Ethnopharmacol 129(1):121–126CrossRefPubMedGoogle Scholar
  20. Wang M, Wang J, Tan R et al (2013, (2013-3-20)) Effect of berberine on PPAR α /NO activation in high glucose- and insulin-induced cardiomyocyte hypertrophy. Evid Based Complement Alternat Med 2013:285489PubMedPubMedCentralGoogle Scholar
  21. Zhang T, Yang S, Du J (2014, (2014-11-13), 2014) Protective effects of berberine on isoproterenol-induced acute myocardial ischemia in rats through regulating HMGB1-TLR4 axis. Evid Based Complement Alternat Med:849783Google Scholar
  22. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK (2002) Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8(5):473–479CrossRefPubMedCentralGoogle Scholar
  23. Nakaya Y, Mawatari K, Takahashi A et al (2007) The phytoestrogen ginsensoside Re activates potassium channels of vascular smooth muscle cells through PI3K/Akt and nitric oxide pathways. J Med Investig 54(3,4):381–384CrossRefGoogle Scholar
  24. Xing Z et al (2018) Synthesis of fibrauretin derivatives and their inhibition of acetylcholinesterase activity. Chin J Anal Chem 5(46):684–689Google Scholar
  25. Sun YY, Yang D, Kuan CY (2012) Mannitol-facilitated perfusion staining with 2,3,5-triphenyltetrazolium chloride (TTC) for detection of experimental cerebral infarction and biochemical analysis. J Neurosci Methods 203(1):122–129CrossRefGoogle Scholar
  26. Chen O, Wang S (2017) High concentration hydrogen protects mouse heart against ischemic/reperfusion injury through activating PI3K/Akt1 pathway. Chin J Circ 32(z1)Google Scholar
  27. Lin L, Chun-Shui P, Li Y et al (2018) Ginsenoside Rg1 ameliorates rat myocardial ischemia-reperfusion injury by modulating energy metabolism pathways. Front Physiol 9:78Google Scholar
  28. Saeidnia S, Gohari AR, Kurepaz-Mahmoodabadi M et al (2014) Phytochemistry and pharmacology of Berberis species. Pharmacogn Rev 8(15):8CrossRefPubMedPubMedCentralGoogle Scholar
  29. Murphy E, Steenbergen C (2007) Gender-based differences in mechanisms of protection in myocardial ischemia–reperfusion injury. Cardiovasc Res 75(3):478–486CrossRefGoogle Scholar
  30. Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia–reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61(3):448–460CrossRefPubMedGoogle Scholar
  31. Jeong J J , Ha Y M , Jin Y C, Lee E.J., Kim J.S., Kim H.J., Seo H.G., Lee J.H., Kang S.S., Kim Y.S., Chang K.C. Rutin from Lonicera japonica inhibits myocardial ischemia/reperfusion-induced apoptosis in vivo and protects H9c2 cells against hydrogen peroxide-mediated injury via ERK1/2 and PI3K/Akt signals in vitro. Food Chem Toxicol, 2009, 47(7):0–1576, 1569CrossRefPubMedGoogle Scholar
  32. Qian L, Yun L, Lin Z et al (2018) GRP78 promotes neural stem cell antiapoptosis and survival in response to oxygen-glucose deprivation (OGD)/reoxygenation through PI3K/Akt, ERK1/2, and NF-\r, κ\r, B/p65 pathways. Oxidative Med Cell Longev 2018:1–12CrossRefGoogle Scholar
  33. Yukang Y, Jun L (2018) Salidroside promotes human periodontal ligament cell proliferation and osteocalcin secretion via ERK1/2 and PI3K/Akt signaling pathways. Exp Ther Med 15(6):5041–5045Google Scholar
  34. Karmakar S, Jin Y, Nagaich AK (2013) Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) α and activator protein 1 (AP1) in dexamethasone-mediated interference of ERα activity. J Biol Chem 288(33):24020–24034CrossRefPubMedGoogle Scholar
  35. Quinn MA, Xu X, Ronfani M, Cidlowski JA (2018) Estrogen deficiency promotes hepatic steatosis via a glucocorticoid receptor-dependent mechanism in mice. Cell Rep 22(10):2690–2701CrossRefPubMedPubMedCentralGoogle Scholar
  36. Kaminska B (2005) MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754(1–2):253–262CrossRefPubMedGoogle Scholar
  37. Zhu L, Yuan C, Huang L et al (2017) The activation of p38MAPK and JNK pathways in bovine herpesvirus 1 infected MDBK cells. Vet Res 47(1):91CrossRefGoogle Scholar
  38. Ashraf MI, Ebner M, Wallner C et al (2014) A p38MAPK/MK2 signaling pathway leading to redox stress, cell death and ischemia/reperfusion injury. Cell Commun Signal 12(1):6–6CrossRefPubMedCentralGoogle Scholar
  39. Maria S, Yana A, Atochina-Vasserman EN et al (2018) c-Jun N-terminal kinases (JNKs) in myocardial and cerebral ischemia/reperfusion injury. Front Pharmacol 9:715CrossRefGoogle Scholar
  40. Ahmad A, Dempsey SK, Daneva Z et al (2018) Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci 19(9):2605CrossRefPubMedCentralGoogle Scholar
  41. Maurizio F, Valeria C, Antonio D et al (2016) Targeting nitric oxide with natural derived compounds as a therapeutic strategy in vascular diseases. Oxidative Med Cell Longev 2016:1–20Google Scholar
  42. Sessa WC (1994) The nitric oxide synthase family of proteins. J Vasc Res 31(3):131–143CrossRefGoogle Scholar
  43. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, O'Rourke B, Rodriguez ER, Huang PL, Lima JA, Berkowitz DE, Hare JM (2002) Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416(6878):337–339CrossRefPubMedGoogle Scholar
  44. Nozaki Y, Fujita K, Wada K et al (2015) Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model. BMC Gastroenterol 15(1):42CrossRefPubMedPubMedCentralGoogle Scholar
  45. Garcia-Bonilla L, Moore JM, Racchumi G et al (2014) Inducible nitric oxide synthase in neutrophils and endothelium contributes to ischemic brain injury in mice. J Immunol 193(5):2531–2537CrossRefPubMedPubMedCentralGoogle Scholar
  46. Mungrue IN, Gros R, You X et al (2002) Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Investig 109(6):735–743CrossRefPubMedGoogle Scholar
  47. Cai X, Wang X, Li J et al (2017) Protective effect of glycyrrhizin on myocardial ischemia/reperfusion injury-induced oxidative stress, inducible nitric oxide synthase and inflammatory reactions through high-mobility group box 1 and mitogen-activated protein kinase expression. Exp Ther Med:1219–1226CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Shenzhen Longhua District Central HospitalShenzhenChina

Personalised recommendations